- Home
- VRAR vs SCYX Comparison
VRAR vs SCYX Comparison
Compare VRAR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- SCYX
- Stock Information
- Founded
- VRAR 2016
- SCYX 1999
- Country
- VRAR United States
- SCYX United States
- Employees
- VRAR N/A
- SCYX N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- SCYX Health Care
- Exchange
- VRAR Nasdaq
- SCYX Nasdaq
- Market Cap
- VRAR 31.5M
- SCYX 28.5M
- IPO Year
- VRAR 2021
- SCYX 2014
- Fundamental
- Price
- VRAR $1.56
- SCYX $0.71
- Analyst Decision
- VRAR Strong Buy
- SCYX
- Analyst Count
- VRAR 1
- SCYX 0
- Target Price
- VRAR $2.62
- SCYX N/A
- AVG Volume (30 Days)
- VRAR 964.2K
- SCYX 182.9K
- Earning Date
- VRAR 05-15-2025
- SCYX 08-07-2025
- Dividend Yield
- VRAR N/A
- SCYX N/A
- EPS Growth
- VRAR N/A
- SCYX N/A
- EPS
- VRAR N/A
- SCYX N/A
- Revenue
- VRAR $8,756,789.00
- SCYX $2,630,000.00
- Revenue This Year
- VRAR $23.96
- SCYX $410.22
- Revenue Next Year
- VRAR $12.15
- SCYX $248.83
- P/E Ratio
- VRAR N/A
- SCYX N/A
- Revenue Growth
- VRAR N/A
- SCYX N/A
- 52 Week Low
- VRAR $0.50
- SCYX $0.66
- 52 Week High
- VRAR $7.00
- SCYX $2.21
- Technical
- Relative Strength Index (RSI)
- VRAR 55.07
- SCYX 43.16
- Support Level
- VRAR $1.52
- SCYX $0.67
- Resistance Level
- VRAR $1.77
- SCYX $0.74
- Average True Range (ATR)
- VRAR 0.16
- SCYX 0.04
- MACD
- VRAR 0.01
- SCYX 0.00
- Stochastic Oscillator
- VRAR 59.09
- SCYX 18.79
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.